GlassScriptPhysician profile
Mayur C Maniar
NPI 1548211204
$13,943.13
in general payments reported to CMS, 2019-2025
59 companies · $893 in 2025
The $893 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,089 · 2020: $2,505 · 2021: $3,655 · 2022: $2,966 · 2023: $1,601 · 2024: $233 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,727.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,994.20 | 2019-2025 | Briviact, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $1,662.23 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,543.05 | 2021-2025 | |
| Allergan, INC. | $1,048.83 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $595.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $562.37 | 2021-2023 | Ponvory |
| Lilly USA, LLC | $474.07 | 2019-2023 | Amyvid |
| Amgen INC. | $431.89 | 2019-2022 | |
| Genzyme Corporation | $417.92 | 2019-2022 | |
| Eisai INC. | $362.49 | 2020-2022 | |
| Emd Serono, INC. | $273.97 | 2019-2025 | |
| Sk Life Science, INC. | $268.21 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $243.89 | 2019-2022 | |
| Acorda Therapeutics, INC | $230.39 | 2019-2023 | Inbrija |
| Lundbeck LLC | $228.77 | 2020-2025 | Vyepti |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayur Maniar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.